BCIQ Profiles

Company Profile ReportTarget Profile Report
0818 Ranok series B
BioCentury & Getty Images

Emerging Company Profile

Ranok: a chaperone-based approach to targeted degradation

Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages

Hangzhou-based Ranok has raised $40 million to test whether its alternative to PROTACs could have safety and dosing advantages.

Aug 18, 2021 | 8:43 PM GMT

An investor syndicate is backing

Read the full 623 word article

How to gain access

Continue reading with a
two-week free trial.